IRIS PubliCatt

Andreotti, Felicita

Andreotti, Felicita  

ROMA - Dipartimento di Scienze cardiovascolari e pneumologiche  

Mostra records
Risultati 1 - 20 di 114 (tempo di esecuzione: 0.027 secondi).
Data di pubblicazione Titolo Autore(i) File
1-gen-2023 PCI for Ischemic Left Ventricular Dysfunction Andreotti, Felicita; Chiariello, Giovanni Alfonso; Massetti, Massimo
1-gen-2022 [Screening for atrial fibrillation: facts and challenges] Andreotti, Felicita; Maggioni, Aldo Pietro; Massetti, Massimo
1-gen-2022 Defining optimal antithrombotic therapy post-TAVI: the contribution of ATLANTIS Andreotti, Felicita; Massetti, Massimo; Ten Berg, Jurrien
1-gen-2022 Oral anticoagulants in fragile patients with percutaneous endoscopic gastrostomy and atrial fibrillation: the ORIGAMI pilot investigation D'Amario, Domenico; Galli, Mattia; Cappannoli, Luigi; Canonico, Francesco; Restivo, Attilio; Arcudi, Alessandra; Scacciavillani, Roberto; E Riccioni, Maria; Vergallo, Rocco; A Montone, Rocco; Conte, Amelia; Meleo, Emiliana; Lancellotti, Stefano; Sacco, Monica; Antonelli, Massimo; Andreotti, Felicita; De Cristofaro, Raimondo; Crea, Filippo
1-gen-2021 Aims: The ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation (ORIGAMI) study investigates the safety and efficacy of Edoxaban administered via PEG in patients with atrial fibrillation and a clinical indication for a long-term anticoagulation. Design: In this prospective, single-centre observational study, 12 PEG-treated patients with indication to anticoagulation will receive edoxaban via PEG and will be followed up to 6 months. Plasma antifactor Xa activity and edoxaban concentrations will be assessed. Thromboembolic (ischaemic stroke, systemic embolism, venous thromboembolism) and bleeding events (Bleeding Academic Research Consortium and Thrombolysis in Myocardial Infarction) will be recorded at 1 and 6 months. Preliminary results: A retrospective analysis of five atrial fibrillation cases undergoing PEG implantation at our Institution who received edoxaban via PEG showed plasma anti-FXa levels at a steady state of 146 ± 15 ng/ml, without major adverse event at a mean follow-up of 6 months. Conclusion: ORIGAMI prospectively investigates PEG-administration of edoxaban in PEG-treated patients requiring long-term anticoagulation. Our preliminary retrospective data support this route of DOAC administration. 1, Domenico D'Amario; Galli, Mattia; Canonico, Francesco; Restivo, Attilio; Arcudi, Alessandra; Scacciavillani, Roberto; Cappannoli, Luigi; Riccioni, Maria Elena; Giuseppina Annetta, Maria; Di Stefano, Gaetano; Piccinni, Carlo; Vergallo, Rocco; Antonio Montone, Rocco; Maria Leone, Antonio; Niccoli, Giampaolo; Sabatelli, Mario; Antonelli, Massimo; Andreotti, Felicita; De Cristofaro, Raimondo; Crea, Filippo
1-gen-2021 Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine Andreotti, Felicita; Maggioni, Aldo Pietro; Campeggi, Alice; Iervolino, Adelaide; Scambia, Giovanni; Massetti, Massimo
1-gen-2021 Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis Navarese, E. P.; Lansky, A. J.; Kereiakes, D. J.; Kubica, J.; Gurbel, P. A.; Gorog, D. A.; Valgimigli, M.; Curzen, N.; Kandzari, D. E.; Bonaca, M. P.; Brouwer, M.; Uminska, J.; Jaguszewski, M. J.; Raggi, P.; Waksman, R.; Leon, M. B.; Wijns, W.; Andreotti, F.
1-gen-2021 Cardiac mortality, adequate power, and objective inclusion of the entire evidence are key to accurately define the long-term effect of revascularisation vs. medical therapy alone in stable coronary syndromes Navarese, E. P.; Andreotti, F.
1-gen-2021 Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men with Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial Zelniker, T. A.; Ardissino, M.; Andreotti, F.; O'Donoghue, M. L.; Yin, O.; Park, J. -G.; Murphy, S. A.; Ruff, C. T.; Lanz, H. J.; Antman, E. M.; Braunwald, E.; Giugliano, R. P.; Merlini, P. A.
1-gen-2021 Doppler Ultrasound Monitoring of Echogenicity in Asymptomatic Subcritical Carotid Stenosis and Assessment of Response to Oral Supplementation of Vitamin K2 (PLAK2 Randomized Controlled Trial) Tshomba, Yamume; Baccellieri, Domenico; Carta, Niccolò; Cilli, Giuseppe; Ardita, Vincenzo; Apruzzi, Luca; Loschi, Diletta; Kahlberg, Andrea; Bertoglio, Luca; Castellano, Renata; Simonini, Elisa; Andreotti, Felicita; Chiesa, Roberto
1-gen-2021 Double or triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: Not a matter of faith Galli, M.; Andreotti, F.; D'Amario, D.; Crea, F.; Porto, I.
1-gen-2021 Efficacy and safety of dual pathway inhibition in patients with cardiovascular disease: a systematic review and Meta-analysis Galli, Mattia; Capodanno, Davide; Benenati, Stefano; D'Amario, Domenico; Crea, Filippo; Andreotti, Felicita; Angiolillo, Dominick J
1-gen-2021 Intracoronary bolus of glycoprotein IIb/IIIa inhibitor as bridging or adjunctive strategy to oral P2Y12 inhibitor load in the modern setting of STEMI Galli, Mattia; Migliaro, Stefano; Rodolico, Daniele; DI Stefano, Gaetano; Piccinni, Carlo; Restivo, Attilio; Andreotti, Felicita; Vergallo, Rocco; Montone, Rocco A; Besis, George; Buffon, Antonio; Romagnoli, Enrico; Aurigemma, Cristina; Leone, Antonio M; Burzotta, Francesco; Niccoli, Giampaolo; Trani, Carlo; Crea, Filippo; D'Amario, Domenico
1-gen-2021 Family history in first degree relatives of patients with premature cardiovascular disease Andreotti, F.; Crea, F.; Patti, G.; Shoulders, C. C.; Navarese, E. P.; Robishaw, J.; Maseri, A.; Hennekens, C. H.
1-gen-2021 From angiotensin-converting enzyme 2 disruption to thromboinflammatory microvascular disease: A paradigm drawn from COVID-19 Vinci, R.; Pedicino, D.; Andreotti, F.; Russo, G.; D'Aiello, A.; De Cristofaro, R.; Crea, F.; Liuzzo, G.
1-gen-2021 Impact of coronary stenting on top of medical therapy and of inclusion of periprocedural infarctions on hard composite endpoints in patients with chronic coronary syndromes: a meta-analysis of randomized controlled trials Galli, Mattia; Vescovo, Giovanni M; Andreotti, Felicita; D'Amario, Domenico; Leone, Antonio Maria; Benenati, Stefano; Vergallo, Rocco; Niccoli, Giampaolo; Trani, Carlo; Porto, Italo
1-gen-2021 Methodological education in response to the quality of COVID-19 publications Andreotti, F.; Gervasoni, C.; Di Pasquale, G.; Maggioni, A. P.
1-gen-2021 ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrIal fibrillation: the (ORIGAMI) study D'Amario, D.; Galli, M.; Canonico, F.; Restivo, A.; Arcudi, A.; Scacciavillani, R.; Cappannoli, L.; Riccioni, M. E.; Annetta, M. G.; Di Stefano, G.; Piccinni, C.; Vergallo, R.; Montone, R. A.; Leone, A. M.; Niccoli, G.; Sabatelli, M.; Antonelli, M.; Andreotti, F.; De Cristofaro, R.; Crea, F.
1-gen-2021 Precision Phenomapping of Acute Coronary Syndromes to Improve Patient Outcomes Andreotti, Felicita; Iervolino, Adelaide; Navarese, Eliano Pio; Maggioni, Aldo Pietro; Crea, Filippo; Scambia, Giovanni
1-gen-2021 Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure Maggioni, A. P.; Dondi, L.; Andreotti, F.; Calabria, S.; Iacoviello, M.; Gorini, M.; Gonzini, L.; Piccinni, C.; Ronconi, G.; Martini, N.